Jazz Pharmaceuticals (JAZZ) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

JAZZ Jazz Pharmaceuticals

Watchlist

125.100
+5.860+4.91%

Close Nov 21 16:00 ET

123.710
-1.390-1.11%

Pre 08:57 ET

7.56BMarket Cap17.72P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Moomoo News08:00 ET · Ratings
Jazz Pharmaceuticals Insiders Sold US$1.7m Of Shares Suggesting Hesitancy
Simply Wall St05:59 ET
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanks05:27 ET · Ratings
Jazz Pharmaceuticals: Promising Growth Potential With Robust Pipeline and Undervalued Market Position
TipRanks12:25 ET
Express News | FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer
Reuters11:22 ET
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
WSJNov 21 09:30 ET

Comments

Stock_Drift

Yesterday 08:32

$Jazz Pharmaceuticals (JAZZ.US)$

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

Stock_Drift

Sep 16 06:45

$Jazz Pharmaceuticals (JAZZ.US)$

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Moomoo AI

Mar 27 06:55

Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.

5.0% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Jazz Pharmaceuticals (NASDAQ:JAZZ) Shareholders Over That Period

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

JAZZ Jazz Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target